Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses

Cellular and Molecular Immunology

Volumn 12, Issue 3, 2015, Pages 273-282

  Ma, Zhiyong ^a,b   Zhang, Ejuan ^c   Yang, Dongliang ^d   Lu, Mengji ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adaptive immune response; Hepatitis B virus; Innate immune response; Toll like receptor

Indexed keywords

1018ISS; AGATOLIMOD; ANTIVIRUS AGENT; CYTOKINE; DOUBLE STRANDED RNA; GS 9620; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; RECOMBINANT HEPATITIS B VACCINE; RINTATOLIMOD; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERABILITY; DUCK HEPATITIS B VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION CONTROL; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; WOODCHUCK HEPATITIS VIRUS; AGONISTS; ANIMAL; B LYMPHOCYTE; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

HEPATITIS B VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; B-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; INTERFERONS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VIRUS REPLICATION;

EID: 84928888455     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.112     Document Type: Review

References (100)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764.
3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
4. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010; 15(Suppl 3): 15-24.
5. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014; 426: 1198-1209.
6. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102-110.
7. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008; 128(3): 400-408.
8. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011; 6: e26315.
9. Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH et al. Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. Antivir Ther 2013; 18: 877-884.
10. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272.
11. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A et al. Tolllike receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46: 1769-1778.
12. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R et al. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012; 57: 522-528.
13. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009; 83: 847-858.
14. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, BraskyKMet al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508-1517, 1517.e1-10.
15. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
16. Szabo G, Billiar TR, Machida K, Crispe IN, Seki E. Toll-like receptor signaling in liver diseases. Gastroenterol Res Pract 2010; 2010: 971270.
17. Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005; 175: 3165-3176.
18. Vanlandschoot P, van Houtte F, Serruys B, Leroux-Roels G. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J Virol 2007; 81: 2535-2536.
19. Vanlandschoot P, van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G. Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. J Gen Virol 2005; 86(Pt 2): 323-331.
20. Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 2009; 182: 6670-6681.
21. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782.
22. Song J, Zhou Y, Li S, Wang B, Zheng X, Wu J et al. Susceptibility of different hepatitis B virus isolates to interferon-Alpha in a mouse model based on hydrodynamic injection. PLoS One 2014; 9: e90977.
23. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-6674.
24. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137: 1289-1300.
25. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011; 55: 762-769.
26. Wilson R, Warner N, Ryan K, Selleck L, Colledge D, Rodgers S et al. The hepatitis B e antigen suppresses IL-1beta-mediated NF-kappaB activation in hepatocytes. J Viral Hepat 2011; 18: e499-e507.
27. Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z. HBsAg inhibits IFNalpha production in plasmacytoid dendritic cells through TNF-Alpha and IL-10 induction in monocytes. PLoS One 2012; 7: e44900.
28. Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013; 190: 5142-5151.
29. Xie Q, Shen HC, Jia NN, Wang H, Lin LY, An BY et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11: 515-523.
30. Xu N, Yao HP, Lv GC, Chen Z. Downregulation of TLR7/9 leads to deficient production of IFN-Alpha from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res 2012; 61: 997-1004.
31. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z et al. HBsAg inhibits TLR9-mediated activation and IFN-Alpha production in plasmacytoid dendritic cells. Mol Immunol 2009; 46: 2640-2646.
32. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R et al. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132-1140.
33. Jiang M, Broering R, Trippler M, Poggenpohl L, Fiedler M, Gerken G et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat 2014; in press.
34. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I-And Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010; 91(Pt 8): 2080-2090.
35. Liu D, Wu A, Cui L, Hao R, Wang Y, He J et al. Hepatitis B virus polymerase suppresses NF-kappaB signaling by inhibiting the activity of IKKs via interaction with Hsp90beta. PLoS One 2014; 9: e91658.
36. Loo YM, Gale Jr. M.Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692.
37. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z et al. The hepatitisBvirus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010; 185: 1158-1168.
38. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 2011; 85: 987-995.
39. Wang X, Li Y, Mao A, Li C, Tien P. Hepatitis B virus X protein suppresses virus-Triggered IRF3 activation and IFN-beta induction by disrupting the VISA-Associated complex. Cell Mol Immunol 2010; 7: 341-348.
40. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010; 6: e1000986.
41. Sajadi SM, Mirzaei V, Hassanshahi G, Khorramdelazad H, Daredor HY, Hosseini SM et al. Decreased expressions of Toll-like receptor 9 and its signaling molecules in chronic hepatitis B virus-infected patients. Arch Pathol Lab Med 2013; 137: 1674-1679.
42. Momeni M, Zainodini N, Bidaki R, Hassanshahi G, Daneshvar H, Khaleghinia M et al. Decreased expression of Toll like receptor signaling molecules in chronic HBV infected patients. Hum Immunol 2014; 75: 15-19.
43. Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R et al. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55: 279-285.
44. Berzsenyi MD, Roberts SK, Preiss S, Woollard DJ, Beard MR, Skinner NA et al. Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-Alpha in HCV & HCV/HIV infection. J Viral Hepat 2011; 18: 852-860.
45. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/ beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173.
46. Zhang X, Meng Z, Qiu S, Xu Y, Yang D, Schlaak JF et al. Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 2009; 11: 1624-1637.
47. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
48. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
49. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-1124.
50. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
51. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al. CD81 T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
52. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL et al. Longitudinal analysis of CD81 T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
53. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
54. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012; 12: 201-213.
55. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010; 34: 1-6.
56. Holz LE, Benseler V, Bowen DG, Bouillet P, Strasser A, O'Reilly L et al. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 2008; 135: 989-997.
57. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J et al. Bimmediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835-1845.
58. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD81 T cells results in antigen-specific T-cell tolerance. Nat Med 2000; 6: 1348-1354.
59. Kern M, Popov A, Scholz K, Schumak B, Djandji D, Limmer A et al. Virally infected mouse liver endothelial cells trigger CD81 T-cell immunity. Gastroenterology 2010; 138: 336-346.
60. Liu J, Jiang M, Ma Z, Dietze KK, Zelinskyy G, Yang D et al. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD81 T cell immunity in vitro. J Immunol 2013; 191: 6178-6190.
61. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003208.
62. Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD81 T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013; 14: 574-583.
63. Lan P, Zhang C, Han Q, Zhang J, Tian Z. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 2013; 58: 73-85.
64. Lv S, Wang J, Dou S, Yang X, Ni X, Sun R et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 2014; 59: 385-394.
65. Wu J, Huang S, Zhao X, Chen M, Lin Y, Xia Y et al. Polyinosinic-polycytidylic acid treatment leads to the interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol 2014; in press.
66. Reynolds JM, Dong C. Toll-like receptor regulation of effector T lymphocyte function. Trends Immunol 2013; 34: 511-519.
67. Cottalorda A, Verschelde C, Marcais A, Tomkowiak M, Musette P, Uematsu S et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 2006; 36(7): 1684-1693.
68. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 2010; 116: 3494-3504.
69. Komai-KomaM, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004; 101: 3029-3034.
70. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic Tlymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008; 22: 3628-3637.
71. Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SNet al. AmplifyingTLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res 2010; 70: 7442-7454.
72. Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J Immunol 2006; 176: 3885-3889.
73. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpGoligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999; 29: 1209-1218.
74. Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini JC, SpeiserDet al. Human effector CD81 T lymphocytes express TLR3 as a functional coreceptor. J Immunol 2006; 177: 8708-8713.
75. Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132: 434-439.
76. Purcell RH, London WT, McAuliffe VJ, Palmer AE, Kaplan PM, Gerin JL et al. Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet 1976; 2: 757-761.
77. Ijichi K, Mitamura K, Ida S, Machida H, Shimada K. In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus. J Med Virol 1994; 43: 161-165.
78. Niu J, Wang Y, Dixon R, Bowden S, Qiao M, Einck L et al. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res 1993; 21: 155-171.
79. Menne S, Tennant BC, Liu KH, Ascenzi MA, Baldwin BH, Bellezza CA et al. Antiviral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 2011; 54: S441.
80. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 2014; 10: e1004210.
81. Huang YW, Hsu CK, Lin SC, Wei SC, Hu JT, Chang HY et al. Reduced Toll-like receptor-9 expression on peripheral CD141 monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther 2014; in press.
82. Durantel D, Zoulim F. Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option? J Hepatol 2012; 57: 486-489.
83. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007; 12: 80-87.
84. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559.
85. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011; 11: 702-712.
86. Nevens F, Zuckerman JN, Burroughs AK, Jung MC, Bayas JM, Kallinowski B et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl 2006; 12: 1489-1495.
87. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-320.
88. Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, WettendorffMet al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20: 3644-3649.
89. Surquin M, Tielemans CL, Kulcsar I, Ryba M, Voros P, Mat O et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-Adjuvanted hepatitis B vaccine. Kidney Int 2010; 77: 247-255.
90. Cooper CL, Davis HL, MorrisML, Efler SM, Adhami MA, Krieg AM et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701.
91. Siegrist CA, Pihlgren M, Tougne C, Efler SM, Morris ML, AlAdhami MJ et al. Co-Administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004; 23: 615-622.
92. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-Administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24: 20-26.
93. Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, DionneMet al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-Administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30: 2556-2563.
94. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007; 7: 1731-1737.
95. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-Treated HIV-infected adults. AIDS 2005; 19: 1473-1479.
96. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-Term seroprotection for up to 5 years. Clin Infect Dis 2008; 46: 1310-1314.
97. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvantcontaining vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011; 10: 417-427.
98. Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, Bhatia SN et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci USA 2014; 111: 12193-1218.
99. Konig A, Doring B, Mohr C, Geipel A, Geyer J, Glebe D. Kinetics of the bile acid transporter and hepatitis B virus receptor Na1/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol 2014; 61: 867-875.
100. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049.